Drug Profile
CGC 11093
Alternative Names: CGC-11093; SL 11093Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Cellgate
- Developer Progen Pharmaceuticals Inc
- Class Antineoplastics; Polyamines
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in USA (IV)
- 24 Jul 2008 Preclinical development is ongoing